✨ Free AI Report
BIOXYTRAN, INC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BIOXYTRAN, INC
Company Research

BIOXYTRAN, INC: Business Overview, Financials & Competitive Analysis

BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization o...

Analyst-debate audio for BIOXYTRAN, INC

AskCyborg analysts argue the bull and bear cases for BIOXYTRAN, INC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

High-risk preclinical biotech pursuing novel oxygen therapeutics and antiviral platforms with uncertain clinical and commercial...

Read the full analyst-debate transcript →
Industry Biotechnology
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest BIOXYTRAN, INC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BIOXYTRAN, INC Overview

Pro stress-test →

BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke.

Strategic Profile

Pro stress-test →

The company highlights a core focus on broad-spectrum antiviral therapies, with its leading antiviral drug candidate ProLectin-M described as a complex carbohydrate therapeutic and galectin antagonist that targets viral entry mechanisms. The company's lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.

Competitive Landscape

Pro stress-test →

BIOXYTRAN competes in early-stage stroke therapeutics against clinical-stage and emerging biotech firms, as well as in antiviral drug development. Direct competition is fragmented across small-cap biotech focusing on niche therapeutic areas (hypoxia, viral infections). Larger pharmaceutical companies are not directly pursuing identical galectin-antagonist antiviral or oxygen-transport stroke platforms, reducing near-term competitive pressure but also suggesting smaller addressable markets.

Industry Context

BIOXYTRAN, INC operates in Biotechnology.

Key facts

Founded: 2008 · Headquarters: Newton, Massachusetts, US · Employees: 3 · Revenue: Estimated $0–$0.5M (no meaningful commercial revenue; clinical-stage biotech) · Market cap: $8.4M

What the analysts stress-tested

The top findings that survived the multi-agent debate for BIOXYTRAN, INC.

  • Completed randomized clinical trial for broad-spectrum antiviral drug (October 2025) and achieved dose optimization of ProLectin-M (May 2025), signaling pipeline advancement but still in clinical stages with no marketed products generating revenue.
  • Lead compound BXT-25 targets ischemic and hemorrhagic stroke through oxygen delivery mechanism; ProLectin-M targets viral diseases as oral antiviral. Dual-platform strategy diversifies risk but requires sustained capital to reach clinical endpoints and commercialization.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Initiation of coverage by Independent Research equity firm
  • November 2025Commercial distribution agreement with Khoury Medical for A-SUQAR dietary supplement
  • +1 moreTrack every material event for BIOXYTRAN, INC as it happens. Explore monitoring →
Get alerted when BIOXYTRAN, INC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Diffuse TherapeuticsDeveloping therapies for stroke and brain injury→Neuralstem IncClinical-stage biotech developing cell therapies for stroke and neurological disorders→Athersys IncClinical-stage biotech developing stem cell therapies for stroke and brain injury→Achaogen IncClinical-stage biotech developing novel antibiotics and antivirals→Bioasis TechnologiesClinical-stage biotech developing therapies for CNS and neurological diseases→

Compare BIOXYTRAN, INC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BIOXYTRAN, INC operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about BIOXYTRAN, INC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BIOXYTRAN, INC and its top competitor on Cyborg Score”
“What did BIOXYTRAN, INC do this quarter?”
“Is BIOXYTRAN, INC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BIOXYTRAN, INC do?+
BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization o...
What is BIOXYTRAN, INC's Cyborg Score?+
BIOXYTRAN, INC has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BIOXYTRAN, INC's main competitors?+
Named competitors include Diffuse Therapeutics, Neuralstem Inc, Athersys Inc, Achaogen Inc. The full competitive landscape is in the AskCyborg report.
How can I get the full BIOXYTRAN, INC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BIOXYTRAN, INC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BIOXYTRAN, INC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score